These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1201 related articles for article (PubMed ID: 18794884)

  • 1. PI3K pathway alterations in cancer: variations on a theme.
    Yuan TL; Cantley LC
    Oncogene; 2008 Sep; 27(41):5497-510. PubMed ID: 18794884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class I PI3K in oncogenic cellular transformation.
    Zhao L; Vogt PK
    Oncogene; 2008 Sep; 27(41):5486-96. PubMed ID: 18794883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
    Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F
    Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relation between PI3K/AKT signalling pathway and cancer.
    Noorolyai S; Shajari N; Baghbani E; Sadreddini S; Baradaran B
    Gene; 2019 May; 698():120-128. PubMed ID: 30849534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
    Millis SZ; Jardim DL; Albacker L; Ross JS; Miller VA; Ali SM; Kurzrock R
    Cancer; 2019 Apr; 125(7):1185-1199. PubMed ID: 30582752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
    Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
    Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should individual PI3 kinase isoforms be targeted in cancer?
    Jia S; Roberts TM; Zhao JJ
    Curr Opin Cell Biol; 2009 Apr; 21(2):199-208. PubMed ID: 19200708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.
    Platt FM; Hurst CD; Taylor CF; Gregory WM; Harnden P; Knowles MA
    Clin Cancer Res; 2009 Oct; 15(19):6008-17. PubMed ID: 19789314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).
    Hafsi S; Pezzino FM; Candido S; Ligresti G; Spandidos DA; Soua Z; McCubrey JA; Travali S; Libra M
    Int J Oncol; 2012 Mar; 40(3):639-44. PubMed ID: 22200790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis.
    Newton HB
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):105-28. PubMed ID: 14748662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
    Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
    BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
    Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
    Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in the clinical development of PI3K inhibitors.
    Massacesi C; di Tomaso E; Fretault N; Hirawat S
    Ann N Y Acad Sci; 2013 Mar; 1280(1):19-23. PubMed ID: 23551097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Status of PI3K inhibition and biomarker development in cancer therapeutics.
    Markman B; Atzori F; Pérez-García J; Tabernero J; Baselga J
    Ann Oncol; 2010 Apr; 21(4):683-691. PubMed ID: 19713247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN and the PI3-kinase pathway in cancer.
    Chalhoub N; Baker SJ
    Annu Rev Pathol; 2009; 4():127-50. PubMed ID: 18767981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
    Carnero A; Blanco-Aparicio C; Renner O; Link W; Leal JF
    Curr Cancer Drug Targets; 2008 May; 8(3):187-98. PubMed ID: 18473732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
    Goltsov A; Faratian D; Langdon SP; Mullen P; Harrison DJ; Bown J
    Cell Signal; 2012 Feb; 24(2):493-504. PubMed ID: 21996585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors.
    Hou P; Ji M; Xing M
    Cancer; 2008 Nov; 113(9):2440-7. PubMed ID: 18831514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K/AKT signaling pathway and cancer: an updated review.
    Martini M; De Santis MC; Braccini L; Gulluni F; Hirsch E
    Ann Med; 2014 Sep; 46(6):372-83. PubMed ID: 24897931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.